default author photo

Ullrich Graeven

Department of Hematology, Oncology and Gastroenterology, Maria Hilf Kliniken

Mönchengladbach

Germany

SCHOLARLY PAPERS

2

DOWNLOADS

147

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Depth of Response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in Front-Line Treatment of High-Risk Multiple Myeloma: Interim Analysis of the GMMG-CONCEPT Trial

Number of pages: 34 Posted: 01 Mar 2021
Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University of Tuebingen, Department of Hematology, Oncology and Bone Marrow Transplantation, Klinikum Chemnitz, Department of Internal Medicine, Charité University Medicine Berlin, Department of Hematology, Oncology and Palliative Care, Klinikum Bielefeld Mitte, Department of Internal Medicine, Hematology and Oncology, Johanniter Krankenhaus Bonn, Department of Hematology and Stem Cell Transplantation, University of Duisburg-Essen, Department of Hematology and Oncology, St. Antonius Hospital Eschweiler, Department of Hematology, Oncology and Immunology, University Hospital of Giessen and Marburg, Internal Medicine V and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Department of Internal Medicine III, University Medical Center Mainz, Department of Hematology, Oncology and Gastroenterology, Maria Hilf Kliniken, Department of Oncology, Hematology and Stem Cell Transplantation, Klinikum Osnabrück, Asklepios Tumorzentrum Hamburg, Institute of Human Genetics, Heidelberg University, Center for Clinical Trials, University Hospitals Tübingen, Division of Biostatistics, German Cancer Research Center (DKFZ), Division of Biostatistics, German Cancer Research Center (DKFZ), Universitatsklinikum Hamburg-Eppendorf, Internal Medicine V and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, University of Hamburg - Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology and Independent
Downloads 92 (730,864)

Abstract:

Loading...

2.

Nal-Iri and 5-FU/LV Compared to 5-FU/LV in Patients with Cholangio- and Gallbladder Carcinoma Previously Treated with Gemcitabine-Based Therapies: The AIO NALIRICC Trial

Number of pages: 24 Posted: 23 Feb 2024
Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Technische Universität München (TUM), University of Hamburg - University Medical Center Hamburg-Eppendorf, Dresden University of Technology - University Clinic Carl Gustav Carus, Charité - Universitätsmedizin Berlin - Berlin Institute of Health, Oncodoc GmbH, HOPE—Practice for Oncology, HELIOS Hospital, Ludwig Maximilian University of Munich (LMU), Leopoldina Hospital Schweinfurt, Heidelberg University, HOPE—Practice for Oncology, HOPE—Practice for Oncology, HOPE—Practice for Oncology, Department of Hematology, Oncology and Gastroenterology, Maria Hilf Kliniken, University of Greifswald - University Hospital Greifswald, Institut für Klinisch-Onkologische Forschung Krankenhaus Nordwest Frankfurt/Main and Schleswig-Holstein University - University Medical Center
Downloads 55 (1,010,164)

Abstract:

Loading...

Cholangiocarcinoma, chemotherapy, Irinotecan, second line